Tag: data integrity

Common Misconceptions About ICH E6(R3) and How to Correct Them Internally Common Misconceptions About ICH E6(R3) and How to Correct Them Internally The principles enshrined in the ICH E6(R3) guidelines are pivotal for maintaining the quality and reliability of clinical trial data. However, several misconceptions exist within the clinical research community regarding its applications and…

Read More “Common Misconceptions About ICH E6(R3) and How to Correct Them Internally” »

Change Management Programs to Roll Out ICH E6(R3) Globally Change Management Programs to Roll Out ICH E6(R3) Globally The implementation of ICH E6(R3) marks a significant evolution in Good Clinical Practice (GCP) guidelines, transitioning towards a more risk-based approach that emphasizes proportionality in clinical trials. This tutorial guide is structured to assist clinical operations, regulatory…

Read More “Change Management Programs to Roll Out ICH E6(R3) Globally” »

ICH E6(R3) Training Strategies for Investigators, CRAs and Study Teams ICH E6(R3) Training Strategies for Investigators, CRAs and Study Teams As clinical trials become increasingly complex, the need for comprehensive training on the ICH E6(R3) guidelines is paramount for all stakeholders involved in the clinical research process. This article provides a step-by-step tutorial aimed at…

Read More “ICH E6(R3) Training Strategies for Investigators, CRAs and Study Teams” »

Aligning ICH E6(R3) With Regional Regulations in the US, EU and UK Aligning ICH E6(R3) With Regional Regulations in the US, EU and UK Introduction to ICH E6(R3) and Its Importance The International Council for Harmonisation (ICH) E6 guideline represents a fundamental component of Good Clinical Practice (GCP) in clinical research management. Updated most recently…

Read More “Aligning ICH E6(R3) With Regional Regulations in the US, EU and UK” »

Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality The increasing complexity of clinical trials demands innovative approaches to vendor and partner oversight. As outlined in the ICH E6(R3) guidelines, these models must reflect a principle of proportionality, ensuring that oversight is commensurate with…

Read More “Vendor and Partner Oversight Models That Reflect ICH E6(R3) Proportionality” »

ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit The paradigm of clinical research has evolved significantly, particularly in the context of the increasing emphasis on patient-centric approaches. As global regulatory bodies such as the FDA, EMA, and MHRA advocate for integrating patient voices in clinical trials, adherence…

Read More “ICH E6(R3) and Patient-Centricity: Rebalancing Burden and Benefit” »

Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence Introduction to Inspection Readiness and ICH E6(R3) The evolving landscape of clinical trials necessitates a framework that enhances compliance and ensures data integrity. The International Council for Harmonisation (ICH) E6(R3) guidelines…

Read More “Inspection Readiness in the Era of ICH E6(R3): New Expectations for Evidence” »

Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio The successful implementation of ICH E6(R3) guidelines requires a comprehensive understanding of roles, responsibilities, and compliance expectations across different functional areas within pharmaceutical and clinical research organizations. In this article, we will provide a step-by-step…

Read More “Cross-Functional RACI Models for Implementing ICH E6(R3) Across the Portfolio” »